## min read

MTHFR Gene Mutation: What It Means for Mental Health

By

Sonia Garcia

|

October 17, 2026

Summarize with AI

MTHFR Gene Mutation: What It Means for Mental Health

Table of Contents

Example H2
Example H3
Example H4
Example H5
Example H6

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

  • C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
  • A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

  • Heterozygous means one copy carries the variant (for C677T, written CT).
  • Homozygous means both copies carry it (TT).
  • Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

  • Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
  • Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

  • An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
  • Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
  • People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
  • If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.

Reccomended for you

# min read

What is the Best Treatment for Schizophrenia?

By

Sonia Garcia

|

October 28, 2026

When someone you love is diagnosed with schizophrenia, the first questions usually come fast. What actually works? Is there a cure? Will they be on medication forever? The answer is more hopeful than many families expect, and more complicated than a single "best" option.

The best treatment for schizophrenia isn't one medication or one therapy. It's a combination: antipsychotic medication to reduce psychotic symptoms, psychosocial treatments to rebuild daily life, support for the family, and, for people early in the illness, a coordinated team that brings all of it together. Treatment works best when it starts early and continues over time.

Can schizophrenia be cured?

There's no cure for schizophrenia in the sense of a treatment that makes it disappear permanently. But recovery is possible, and more common than many people realize. According to the WHO, at least one in three people with schizophrenia will be able to fully recover.

The goal of treatment, as the NIMH describes it, is to help people manage their symptoms, improve day-to-day functioning, and reach personal goals such as finishing school, working, and having fulfilling relationships.

People often search for "how to cure schizophrenia permanently." Be wary of any program, supplement, or provider that promises a permanent cure. The approaches below are the ones with evidence behind them.

Antipsychotic medication

Antipsychotics are the foundation of treatment for most people with schizophrenia. According to the NIMH, they can make psychotic symptoms such as hallucinations and delusions less intense and less frequent. Most are taken daily as a pill or liquid. Some come as an injection given once or twice a month.

Is there a "best" medication for schizophrenia?

No single antipsychotic is best for everyone. People respond differently, and the NIMH notes that some people need to try several medications before finding the one that works best for them.

The bigger differences between antipsychotics are often in side effects. The NIMH lists weight gain, dry mouth, restlessness, and drowsiness as common early side effects. A 2020 network meta-analysis in The Lancet Psychiatry of 100 trials and 25,952 patients compared 18 antipsychotics and found large differences in their effects on weight, cholesterol, and blood sugar. Clozapine and olanzapine were among those with the largest metabolic changes. That's one reason medication choice is individual, and why physical health monitoring matters during treatment.

The NIMH also advises against stopping an antipsychotic without talking to a health care provider first, so that changes can be made safely.

Clozapine for treatment-resistant schizophrenia

When symptoms don't improve with usual antipsychotics, the NIMH notes that clozapine may be prescribed. People taking clozapine need regular blood tests to check for a potentially dangerous side effect that occurs in 1% to 2% of patients.

Long-acting injectable antipsychotics

Long-acting injectables (LAIs) are given every few weeks or months rather than taken daily. A 2021 meta-analysis in The Lancet Psychiatry of 137 studies with nearly 400,000 patients found that LAIs were associated with a lower risk of hospitalization or relapse than oral antipsychotics across randomized trials, cohort studies, and before-and-after studies. The difference was modest in randomized trials and larger in real-world data.

Psychosocial treatments

Medication reduces psychotic symptoms. It doesn't, on its own, rebuild a life. According to the NIMH, people who take part in regular psychosocial treatment are less likely to have symptoms come back or to be hospitalized. Examples include:

  • Cognitive behavioral therapy (CBT): helps people work with distressing beliefs and voices and build coping strategies
  • Behavioral skills training: builds social and daily living skills
  • Supported employment: helps people find and keep jobs
  • Cognitive remediation: targets attention, memory, and problem-solving, which the NIMH notes are among the best predictors of day-to-day functioning

Family education and support

Schizophrenia affects the whole family. The NIMH notes that educational programs help family and friends understand symptoms and treatment options, manage their own distress, and support their loved one more effectively.

Treatment for co-occurring substance use

Many people with schizophrenia also use drugs or alcohol. The NIMH emphasizes that treating both together matters, because substance use can interfere with treatment for schizophrenia.

Coordinated specialty care for early psychosis

For people early in the illness, coordinated specialty care (CSC) is the model with the strongest support. It's a team approach for first-episode psychosis that combines psychotherapy, medication, case management, employment and education services, and family education and support, with the person involved in every treatment decision. According to the NIMH, compared with typical care, CSC is more effective in reducing symptoms, improving quality of life, and increasing involvement in work or school.

For people who are likely to face repeated hospitalizations or homelessness, assertive community treatment brings a team of providers to the person in the community.

Why early treatment matters

Timing changes outcomes. The NIMH notes that people with psychosis often have symptoms for more than a year before getting treatment, and that early treatment often means better recovery. If you're seeing early warning signs, such as withdrawal, suspiciousness, or a drop in functioning, an evaluation shouldn't wait. Our article on psychosis vs. schizophrenia covers those signs in more detail.

How we treat schizophrenia at Amae Health

Schizophrenia, schizoaffective disorder, and first-episode psychosis are among the conditions our clinics specialize in. Our care teams bring psychiatrists, therapists, primary care physicians, dietitians, peer mentors, and care coordinators under one roof, working from one treatment plan. That means medication, therapy, physical health, and practical support are handled together. For people who need more than weekly care, we offer an Intensive Outpatient Program (IOP) and a Partial Hospitalization Program (PHP). For a broader overview, see schizophrenia treatment options.

Frequently asked questions

Can schizophrenia be cured?

There's no permanent cure, but recovery is possible. The WHO reports that at least one in three people with schizophrenia will be able to fully recover, and treatment aims to help people manage symptoms and reach their personal goals.

What is the first-line treatment for schizophrenia?

Antipsychotic medication is the foundation, usually combined with psychosocial treatments such as CBT, skills training, and family education. For first-episode psychosis, coordinated specialty care brings these together in one team.

What is the best medication for schizophrenia?

There isn't one best medication for everyone. Antipsychotics differ mainly in side effects, and people often try more than one before finding the right fit. Clozapine is used when other antipsychotics haven't worked, and long-acting injectables offer an alternative to a daily pill.

Will someone with schizophrenia need medication forever?

Schizophrenia usually requires ongoing treatment, and the right plan depends on the person's history and response. Decisions about changing or stopping medication should always be made with a health care provider, never alone.

Can schizophrenia be treated without medication?

Psychosocial treatments are essential, but for most people they work alongside medication rather than replacing it. The trade-offs are different for every person and belong in a conversation with their care team.

Key takeaways

  • The best treatment for schizophrenia combines antipsychotic medication, psychosocial treatments, and family support.
  • No single antipsychotic is best for everyone. Side effects differ widely, and clozapine helps when others don't.
  • Long-acting injectables are associated with fewer relapses and hospitalizations than daily pills.
  • Coordinated specialty care is the standard for first-episode psychosis, and early treatment leads to better recovery.
  • There's no cure, but at least one in three people with schizophrenia fully recover.

If you or someone you love is living with schizophrenia or showing early signs of psychosis, request an intake appointment. Our team will explain how an evaluation works and what to expect from the first visit.

# min read

Telepsychiatry vs In-Person Care for Serious Mental Illness

By

Sonia Garcia

|

October 23, 2026

Weighing telepsychiatry vs in-person care means holding two findings at once. Across many mental health conditions, video psychiatry performs about as well as sitting in the same room. For severe mental illness (SMI) such as schizophrenia and bipolar disorder, the trials simply have not been run, and parts of this care (injections, blood tests, physical checks, and crisis assessment) cannot travel through a screen at all. So the real question is rarely either-or. It is which parts of care can safely go virtual, which parts cannot, and who should be making that call as your stability changes over time. Here's what the research shows, and where the practical limits fall.

What Telepsychiatry Is and What In-Person Care Means

Telepsychiatry is psychiatric care delivered by video or phone: evaluations, medication visits, and therapy sessions held from wherever the patient is. In-person care means visits at a clinic, with the clinician and everything a clinic contains (labs, injections, vitals, a team down the hall) physically present. Between them sits hybrid care, a deliberate mix of both formats, which is how a great deal of psychiatric care in the United States now actually runs. The terms matter less than what each format can physically deliver, which is where the comparison gets concrete.

What the Research Shows

The broadest comparison to date is a 2023 meta-analysis in the British Journal of Psychiatry covering 32 randomized trials and 3,592 participants across 11 conditions (Hagi et al., 2023). Pooled together, there was no significant overall difference in symptom improvement between telepsychiatry and face-to-face treatment. By condition, telepsychiatry did better for depressive disorders, across 6 trials, and face-to-face did better for eating disorders, on the strength of a single trial. Dropout findings split the same way, each direction supported by one small study. Several of the condition-level results rest on a single trial, which makes them fragile rather than final, and the authors note as much.

That finding cuts in both directions. Video care is not a watered-down version of psychiatry; for depression in particular it holds up well, and dismissing it would misread the data. At the same time, a pooled average across 11 conditions says nothing about the conditions that never made it into the trials, and the trials skew toward the diagnoses that are easiest to study remotely.

What We Know, and Do Not Yet Know, About SMI

Schizophrenia and bipolar disorder are largely missing from this evidence. A 2022 systematic review in JMIR Mental Health went looking for randomized trials of telehealth psychotherapy and found 12 trials with 931 patients, none of which studied schizophrenia or bipolar disorder, leading the authors to call for high-quality research before treating telehealth as equivalent for these conditions (Greenwood et al., 2022). The Hagi meta-analysis likewise names neither condition among its findings. Narrative reviews describe telehealth with psychosis as feasible and acceptable, and feasibility is a different claim than tested equivalence.

The absence of strong trials is not proof that telepsychiatry harms people with severe mental illness, and it is not proof of equivalence either. For conditions this serious, that gap counsels care in what gets moved online, and it puts the burden on care models to show their format choices serve the patient rather than the schedule.

What Needs to Happen In Person

Some components of SMI treatment are physical, and no quality of webcam changes that:

  • Long-acting injectable antipsychotics are administered by a clinician, on a schedule, in person. For many people they are the backbone of stability.
  • Blood monitoring comes with several core SMI medications: lithium levels, the regular blood counts recommended with clozapine, and metabolic monitoring for people on antipsychotics, per each medication's prescribing requirements. These need a clinic or a lab, not a login.
  • Physical exams and vitals catch the medical problems that psychiatric medications can cause and that psychiatric illness so often hides from everyone, including the patient.
  • Interventional treatments such as TMS and Spravato are delivered in clinic under supervision, by design.
  • Crisis assessment is a hands-on clinical skill. Judging safety through a screen, with a person who may not want to be seen clearly and can end the call at will, is a genuinely harder task than assessing someone in the room.

For severe mental illness, these are routine, recurring parts of treatment rather than rare events, which is why fully remote care for this population runs into walls that have nothing to do with anyone's opinion of telehealth. A care plan that includes an injectable every four weeks and quarterly labs has an in-person spine no matter how the conversations happen.

Where Telepsychiatry Fits Well

Video visits earn their place in several situations: stable follow-ups and medication check-ins once a plan is working, access for people who live far from psychiatric care or cannot travel easily, and flexibility for family members joining a session from different places. For a routine fifteen-minute medication review in a stable month, driving an hour each way serves nobody.

Those are real advantages, and they come with real conditions. A video visit requires privacy at home, which not every household offers, a reliable connection, and the ability to engage through a screen, each of which gets harder exactly when symptoms are most active. Paranoia can make a camera feel threatening; depression can make logging in feel impossible. The format works best for the stable stretches of an illness that does not always stay stable.

Hybrid Care and Level of Need

The workable frame is level of need rather than loyalty to a format. Someone newly stabilized after a hospitalization needs more in-person contact: labs, physical checks, possibly injections, a team reading them closely. Someone two stable years into treatment may handle routine visits by video and come in for bloodwork and periodic full evaluations. A rough month might mean temporarily moving visits back on site.

The mix should shift as stability shifts, in both directions, and the people best positioned to adjust it are a care team who knows the whole picture, the same logic that separates outpatient from inpatient levels of care.

Why a Coordinated, In-Person Team Matters for SMI

Severe mental illness is a whole-body, whole-life illness, and people living with it face higher rates of serious physical illness, so treating it takes more than a sequence of appointments in any format. At Amae Health, one team (psychiatrists, therapists, and primary care physicians, along with peer mentors, care coordinators, dietitians, and health coaches) works from a shared plan in one place, so the injection, the lab draw, the therapy session, and the medical follow-up belong to one plan rather than four calendars. That is the part of care a screen cannot substitute for: not the conversation, which video carries fine, but the coordination and the physical medicine around it. It is the model behind our psychosis care and bipolar disorder treatment, and our full care model shows how the pieces fit.

Talking to Our Care Team About the Right Format

The right format is a clinical question with a moving answer: it depends on your current symptoms, your medications and their monitoring, your stability, and your goals. A first conversation can settle where to start and how to adjust from there. Reach out to our care team about the right format for this stage, and our patient and family resources describe what coordinated care involves.

Frequently Asked Questions

Is telepsychiatry as effective as in-person psychiatry?

For many conditions, yes. A 2023 meta-analysis of 32 randomized trials found no significant overall difference in symptom improvement, and telepsychiatry did best for depressive disorders. Results vary by condition, and evidence for schizophrenia and bipolar disorder specifically is limited.

Is telepsychiatry effective for schizophrenia?

The research is thin. A 2022 systematic review found no eligible randomized trials of telehealth psychotherapy for schizophrenia, while narrative reviews describe telehealth with psychosis as feasible and acceptable. Limited research is the accurate summary, not evidence of failure.

Can long-acting injectable antipsychotics be given by telehealth?

No. Injections are administered in person by a clinician, so people on long-acting injectables need in-person visits on their injection schedule, whatever else happens by video.

Do I need blood tests or physical checks with serious mental illness?

Often, yes, depending on the medication. Lithium requires blood level checks, clozapine calls for regular blood monitoring, and antipsychotics call for metabolic monitoring under their prescribing requirements, all of which involve a clinic or lab visit.

Can telepsychiatry handle a mental health crisis?

No. Video visits are not built for emergencies. In a crisis, call or text 988 or go to the nearest emergency room; a care team can take over treatment planning once the person is safe.

What is hybrid psychiatric care?

A deliberate mix of in-person and video visits, adjusted over time as stability and needs change. In-person time covers the parts of care that require presence, such as injections and labs, while routine check-ins can happen by video.

What if I am having thoughts of suicide?

Help is available right now, at any hour: call or text 988 for free, confidential support.

Citations

  1. Hagi K, et al. "Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials." British Journal of Psychiatry, 2023;223(3):407-414. doi.org/10.1192/bjp.2023.86. Tier 1 (peer-reviewed meta-analysis).
  2. Greenwood H, et al. "Telehealth versus face-to-face psychotherapy for less common mental health conditions: systematic review and meta-analysis." JMIR Mental Health, 2022;9(3):e31780. PMC8956990. Tier 1 (peer-reviewed systematic review).
  3. 988 Suicide and Crisis Lifeline. 988lifeline.org. Tier 2 (FAQ only).

# min read

What is Attention-Seeking Behavior?

By

Sonia Garcia

|

October 22, 2026

Someone calls a friend "such an attention seeker," and everyone nods. Maybe it's a coworker who turns every meeting into a story about themselves, a partner who escalates every disagreement, or a teenager whose posts get more dramatic by the week. Or maybe you've wondered whether the label fits you.

Attention-seeking behavior is any behavior aimed, consciously or not, at getting other people to notice, respond, or reassure. Everyone does it sometimes. Wanting to be seen is a basic human need. It becomes a problem when it's persistent, when it disrupts relationships or work, or when it's the visible edge of something harder underneath: loneliness, a mood episode, a personality disorder, or a crisis.

What counts as attention-seeking behavior?

Common examples include:

  • Exaggerating stories or symptoms to get a reaction
  • Steering conversations back to yourself
  • Dramatic emotional displays out of proportion to the situation
  • Fishing for compliments or reassurance
  • Provocative statements, posts, or clothing meant to stand out
  • Starting conflict to get engagement, even negative engagement

None of these, on its own, says anything about mental health. Context matters more than any single behavior: how often it happens, how much it costs the person, and what's driving it.

Why do people seek attention?

There's rarely a single reason. Common drivers include:

  • Loneliness and unmet needs for connection. When people feel unseen, any response can feel better than none.
  • Low self-worth. External validation can stand in for an internal sense of being okay.
  • Learned patterns. In some families, the only reliable way to get a response was to escalate. Habits learned early can carry into adulthood.
  • Stress or crisis. Even people who rarely seek attention may reach for it during a breakup, a loss, or a period of instability.
  • Social media. Likes and comments offer fast, measurable attention, which makes it easy to chase.

Sometimes, though, behavior that looks like attention-seeking is a symptom of a mental health condition, and treating it as a character flaw misses the point.

Is attention-seeking behavior a sign of a disorder?

Usually not. But persistent, intense attention-seeking can be part of several conditions.

"Attention-seeking disorder" isn't a real diagnosis

People often search for "attention seeking disorder." There's no condition by that name in the DSM-5. The diagnosis most closely tied to attention-seeking is histrionic personality disorder, and attention-seeking can also show up in borderline personality disorder, narcissistic personality disorder, and during manic episodes of bipolar disorder.

Histrionic personality disorder

Histrionic personality disorder (HPD) is defined by a long-standing pattern of excessive emotionality and attention-seeking. According to the MSD Manual, it affects about 2% of people in the U.S. Under DSM-5-TR criteria, a diagnosis requires at least five of the following, beginning by early adulthood:

  • Discomfort when not the center of attention
  • Inappropriately seductive or provocative interactions
  • Rapidly shifting, shallow-seeming emotions
  • Consistent use of physical appearance to draw attention
  • Speech that is vague and lacking in detail
  • Dramatic, theatrical, exaggerated emotional expression
  • Being easily influenced by others or situations
  • Seeing relationships as more intimate than they are

A StatPearls review on NCBI describes HPD as an enduring condition that typically begins in late adolescence or early adulthood. The key difference from ordinary attention-seeking is that the pattern is pervasive: it shows up across relationships and settings, for years, and causes real distress or impairment.

Borderline personality disorder

In borderline personality disorder (BPD), intense fear of abandonment, unstable relationships, and rapidly shifting moods can lead to behavior that others read as attention-seeking. Usually it's something closer to panic: an attempt to keep someone from leaving. BPD can also look the opposite way, turned inward. We've written about that in quiet BPD and about the outward-facing petulant type of BPD.

Bipolar disorder

During a manic episode, the NIMH describes symptoms such as feeling very up or elated, talking fast about many things, feeling unusually important, talented, or powerful, and an excessive appetite for pleasurable activities. To others, that can look like a bid for attention. It's actually a mood episode, and it needs treatment.

When "attention-seeking" is really a cry for help

Talk of suicide, self-harm, or hopelessness is sometimes dismissed as "just attention-seeking." That's dangerous. The NIMH's warning signs of suicide include talking about wanting to die, feeling like a burden, feeling hopeless or trapped, and withdrawing from friends. These are reasons to respond, not to roll your eyes.

Even if someone has said similar things before, take it seriously. Ask directly. Stay with them. If you or someone you know is in danger, call or text 988, the Suicide & Crisis Lifeline, or call 911.

How attention-seeking affects relationships

Persistent attention-seeking tends to wear people down. Friends and partners can feel exhausted, manipulated, or stuck in cycles of crisis and reconciliation. Over time, people pull back, which deepens the loneliness that often drove the behavior in the first place.

That cycle is why labeling someone an "attention seeker" rarely helps. It names the behavior without touching the need underneath.

What helps

When attention-seeking is a habit rather than a symptom, change usually starts with noticing the need before acting on it. Is it reassurance, connection, recognition? Saying that need directly often gets a better response than dramatizing it.

When it's part of a mental health condition, treatment targets the condition:

  • Personality disorders. Psychotherapy is the main treatment. The MSD Manual notes that for HPD, psychotherapy focusing on underlying conflicts may help. For BPD, a 2020 Cochrane review found that psychotherapy reduced symptom severity, with dialectical behavior therapy and mentalization-based treatment the most studied.
  • Bipolar disorder. According to the NIMH, bipolar disorder usually requires lifelong treatment, typically medication combined with psychotherapy.

If you're on the other side of it, as a partner, parent, or friend, it helps to respond to the underlying need calmly and consistently, while setting clear limits on behavior you can't sustain. For more, see how to help someone with mental health issues.

When to look for more support

Consider a professional evaluation when attention-seeking is constant, damages relationships or work, comes with intense mood swings or fear of abandonment, or comes with any talk of self-harm.

At Amae Health, our clinics specialize in conditions including Borderline Personality Disorder and bipolar disorder. Our care teams bring psychiatrists, therapists, peer mentors, and care coordinators under one roof, working from one treatment plan, so the pattern behind the behavior gets looked at, not just the behavior itself.

Frequently asked questions

What is an attention seeker?

"Attention seeker" is an informal label for someone who often behaves in ways meant to draw notice or reactions from others. It isn't a diagnosis, and it often oversimplifies what's going on.

Is attention-seeking a mental illness?

No. Attention-seeking is a behavior, not a diagnosis. Persistent, pervasive attention-seeking can be part of histrionic personality disorder, and it can also appear in borderline personality disorder and during manic episodes of bipolar disorder.

What causes attention-seeking behavior in adults?

Common drivers include loneliness, low self-worth, patterns learned in childhood, stress or crisis, and the pull of social media. In some cases, it's a symptom of a mental health condition.

How do you respond to someone who is attention-seeking?

Respond to the need behind the behavior, such as reassurance or connection, without rewarding escalation. Set calm, consistent limits. And never dismiss talk of suicide or self-harm as attention-seeking.

Key takeaways

  • Attention-seeking behavior is common and human. It becomes a concern when it's persistent and harmful.
  • "Attention-seeking disorder" isn't a diagnosis. Histrionic personality disorder is the condition most closely tied to it, and it can also appear in BPD and bipolar disorder.
  • Talk of suicide or self-harm should always be taken seriously, never written off as attention-seeking.
  • The most useful response is to address the need underneath the behavior.

If attention-seeking is part of a bigger pattern of mood swings, unstable relationships, or self-harm, for you or someone you love, request an intake appointment. Our team will explain how an evaluation works and what to expect from the first visit.